Helsinn And BridgeBio Ink Infigratinib Cancer Pact
Duo Will Co-develop And Commercialise FGFR1-3 inhibitor In Oncology
Executive Summary
Helsinn’s strategic collaboration with BridgeBio Pharma to co-develop and commercialise candidate FGFR1-3 inhibitor infigratinib in oncology will give the Swiss family-owned company its first targeted cancer therapeutic for the US market, its CEO tells Scrip.
You may also be interested in...
BridgeBio, Helsinn Partner Again After Truseltiq Success
Deal Snapshot: The two firms will seek to co-develop and co-commercialize targeted small molecule cancer therapies that they identify at the preclinical stage.
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.